Pregnancy test: Research Studies

15 Related Result(s)

  1. Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

    To compare the complete response rate at 6 cycles after randomization as defined by centrally read PET/CT (integral biomarker) of 2 targeted therapeutic...

  2. A Phase II Study to Assess the Activity of PD-L Inhibition with Durvalumab (MEDI4736) after Chemo-Radiotherapy in Patients with Stage II-IV Microsatellite Stable (MSS) Rectal Cancer

    ...

  3. Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

    To determine the efficacy, based on PFS, of mFOLFOX6/bevacizumab plus atezolizumab (combination) and atezolizumab (single agent) as compared to mFOLFOX6...

  4. LUN005-12: A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

    Establish the maximum tolerated dose of radiotherapy using hypo-fractionated proton therapy concurrently with chemotherapy and determine the percentage of...

  5. Phase 1a/1b Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    The primary objective of the Phase 1a dose-escalation study is to determine the RD and DLTs of SBP-101 when administered in combination with standard dose...

  6. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    The primary objective of this study is to compare the overall survival (OS) of patients receiving intravenous (IV) rigosertib to the OS of patients receiving...

  7. A Phase Ib/II Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects with Resistant Acute Myeloid Leukemia (AML)

    Phase Ib: Establish the maximum tolerated dose (MTD) of oral ciprofloxacin when given in combination with a fixed dose of oral etoposide. Phase II: Determine...

  8. Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms

    The primary objective is to determine the response rate for subject with mutations in BAP1 and other genes...

  9. A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors

    This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent...

  10. LCCC 1612: P53 mutational status and circulating free HPV DNA for the management of HPV-associated Oropharyngeal Squamous Cell Cancers

    Primary Objective:  ...

Pages